GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP
(Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line
treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).